

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 July 2025 (03.07.2025)



(10) International Publication Number
WO 2025/141129 A1

(51) International Patent Classification:

A61K 38/26 (2006.01) *A61K 47/18* (2017.01)
A61K 9/08 (2006.01) *A61P 1/00* (2006.01)
A61K 9/00 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

(21) International Application Number:

PCT/EP2024/088520

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
— *in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE*

(22) International Filing Date:

27 December 2024 (27.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23220527.8 28 December 2023 (28.12.2023) EP

(71) Applicant: **ZEALAND PHARMA A/S** [DK/DK]; Syd-
marken 11, 2860 Soborg (DK).

(72) Inventors: **MELANDER, Claes**; c/o ZEALAND
PHARMA A/S, Sydmarken 11, 2860 Soborg (DK).
LUNDQVIST, Joakim; c/o ZEALAND PHARMA A/
S, Sydmarken 11, 2860 Soborg (DK). **ADRIANSEN,
Mikkel**; c/o ZEALAND PHARMA A/S, Sydmarken 11,
2860 Soborg (DK).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Coun-
terslip, Bristol BS1 6BX (GB).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE 2 (GLP-2) ANALOGUES AND THEIR USES

(57) Abstract: Liquid formulations of GLP-2 analogues that make them suitable for long term storage as liquids and/or that makes them especially suitable for delivery by a drug delivery device are described. In particular, it has been found that one of the main, specified, degradation products are equally or more potent than gilepaglutide and is responsible for approximately half of the loss in content of gilepaglutide, in particular the degradation product that forms when the Asp residue at a position corresponding to position 33 of native human GLP-2 isomerises to form an Iso-Asp/Beta Asp residue.



WO 2025/141129 A1